2019 (Page 2)

Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans

Valic MS & Zheng G Theranostics, 2019 DOI: 10.7150/thno.34509 A critical step in the translational science of nanomaterials from preclinical animal studies to humans is the comprehensive investigation of their disposition (or ADME) and pharmacokinetic behaviours. Disposition and pharmacokinetic data are ideally collected in different animal species (rodent and nonrodent),Continue Reading

Rational design of photosynthesis-inspired nanomedicines

Harmatys KM, Overchuk M & Zheng G Accounts of Chemical Research, 2019 DOI: 10.1021/acs.accounts.9b00104 The sun is the most abundant source of energy on earth. Phototrophs have discovered clever strategies to harvest this light energy and convert it to chemical energy for biomass production. This is achieved in light-harvesting complexes,Continue Reading

Use of porphysomes to detect primary tumour, lymph node metastases, intra-abdominal metastases and as a tool for image-guided lymphadenectomy: Proof of concept in endometrial cancer

Philp L, Chan H, Rouzbahman M, Overchuk M, Chen J, Zheng G & Bernardini MQ Theranostics, 2019 DOI: 10.7150/thno.31225 Objective: To investigate Porphysome fluorescence image-guided resection (PYRO-FGR) for detection of uterine tumour, metastatic lymph nodes and abdominal metastases in a model of endometrial cancer. Methods: White New Zealand rabbits wereContinue Reading

Tailoring porphyrin conjugation for nanoassembly-driven phototheranostic properties

Overchuk M, Zheng M, Rajora MA, Charron DM, Chen J & Zheng G ACS Nano, 2019 DOI: 10.1021/acsnano.9b00494 Lipoprotein mimetic nanostructures, which consist of an amphiphilic lipid shell, a hydrophobic core, and an apolipoprotein mimetic peptide, serve as a versatile platform for the design of drug delivery vehicles as wellContinue Reading

Advancing cancer immunotherapies with nanotechnology

Lou J, Zhang L & Zheng G Advanced Therapeutics, 2019 DOI: 10.1002/adtp.201800128 Cancer immunotherapies can elicit long term, durable responses in only a fraction of patients. As such, there is a need to increase the number of patients who can benefit from cancer immunotherapies. By virtue of their versatility andContinue Reading